Zhu Xiaofu, Joy Anil Abraham
Division of Medical Oncology, Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta and Cross Cancer Institute, 11560 University Avenue, Edmonton, AB, Canada, T6G 1Z2.
Methods Mol Biol. 2017;1652:63-77. doi: 10.1007/978-1-4939-7219-7_4.
Human epidermal growth factor receptor 2 (HER2) is a human oncogene that is amplified in approximately 20% of breast cancers, and portends a worse prognosis if not treated with anti-HER2 agents. The advent of targeted anti-HER2 therapies has dramatically improved disease control and survival in patients with metastatic HER2-positive breast cancer, and is now considered standard of care in the first-line setting and beyond. This review summarizes the currently available data on targeted anti-HER2 therapies from completed randomized phase III clinical trials, and briefly discusses emerging advances that will address unmet needs in metastatic HER2-positive breast cancer.
人表皮生长因子受体2（HER2）是一种人类癌基因，在约20%的乳腺癌中呈扩增状态，若不采用抗HER2药物治疗，其预后较差。靶向抗HER2治疗方法的出现显著改善了转移性HER2阳性乳腺癌患者的疾病控制情况和生存率，目前已被视为一线及后续治疗的标准方案。本综述总结了已完成的随机III期临床试验中关于靶向抗HER2治疗的现有数据，并简要讨论了能够满足转移性HER2阳性乳腺癌未满足需求的新进展。
